Rachelle Suzanne Jacques Sells 1,993 Shares of uniQure (NASDAQ:QURE) Stock

uniQure N.V. (NASDAQ:QURE) Director Rachelle Suzanne Jacques sold 1,993 shares of uniQure stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $27.06, for a total transaction of $53,930.58. Following the completion of the transaction, the director owned 33,903 shares of the company’s stock, valued at $917,415.18. This trade represents a 5.55% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

uniQure Price Performance

Shares of NASDAQ:QURE traded up $0.75 during trading on Friday, reaching $27.57. The stock had a trading volume of 835,627 shares, compared to its average volume of 2,601,234. uniQure N.V. has a 52 week low of $8.73 and a 52 week high of $71.50. The business’s 50-day moving average price is $22.31 and its 200 day moving average price is $21.76. The company has a debt-to-equity ratio of 0.33, a current ratio of 10.40 and a quick ratio of 10.40. The stock has a market capitalization of $1.74 billion, a PE ratio of -7.92 and a beta of 0.98.

uniQure (NASDAQ:QURE) last posted its earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.03. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. The company had revenue of $3.56 million during the quarter, compared to analysts’ expectations of $5.21 million. As a group, equities analysts predict that uniQure N.V. will post -3.64 earnings per share for the current year.

Hedge Funds Weigh In On uniQure

Institutional investors and hedge funds have recently made changes to their positions in the company. Jones Financial Companies Lllp grew its holdings in shares of uniQure by 509.0% in the 3rd quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock valued at $33,000 after buying an additional 509 shares during the period. CIBC Private Wealth Group LLC acquired a new position in shares of uniQure in the 3rd quarter valued at $50,000. Torren Management LLC acquired a new position in shares of uniQure in the 4th quarter valued at $28,000. FNY Investment Advisers LLC grew its holdings in shares of uniQure by 76.7% in the 3rd quarter. FNY Investment Advisers LLC now owns 1,654 shares of the biotechnology company’s stock valued at $96,000 after buying an additional 718 shares during the period. Finally, IFP Advisors Inc acquired a new position in shares of uniQure in the 4th quarter valued at $48,000. Institutional investors and hedge funds own 78.83% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently weighed in on QURE shares. Cantor Fitzgerald restated a “neutral” rating and issued a $9.00 price objective (down from $55.00) on shares of uniQure in a research report on Monday, March 2nd. Royal Bank Of Canada upgraded shares of uniQure from a “sector perform” rating to an “outperform” rating and boosted their price objective for the stock from $11.00 to $35.00 in a research report on Monday, March 9th. Leerink Partners reaffirmed an “outperform” rating and set a $35.00 target price on shares of uniQure in a report on Monday, March 2nd. Sanford C. Bernstein lowered shares of uniQure to a “market perform” rating in a report on Tuesday, March 3rd. Finally, TD Cowen reaffirmed a “buy” rating on shares of uniQure in a report on Tuesday, March 3rd. Ten research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, uniQure presently has an average rating of “Moderate Buy” and an average target price of $42.83.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno?associated viral (AAV) vector platform, the company designs single?dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.